|
Abnormal nasal morphology
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Abnormal tricuspid valve morphology
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Abnormality of cardiovascular system morphology
|
0.110 |
Biomarker
|
disease |
HPO |
|
|
|
|
Abnormality of cardiovascular system morphology
|
0.110 |
GeneticVariation
|
disease |
BEFREE |
Verified segmental deletion or duplications were not directly associated with cardiovascular malformations except in DAAM1 and GATA6.
|
23678296 |
2013 |
|
Abnormality of metabolism/homeostasis
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Abnormality of the skeletal system
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Adenocarcinoma
|
0.050 |
Biomarker
|
group |
BEFREE |
A gene network centered on hepatic nuclear factor and GATA6 was identified in AC, suggesting a role in glandular cell differentiation of the cervix.
|
21407225 |
2011 |
|
Adenocarcinoma
|
0.050 |
Biomarker
|
group |
BEFREE |
PCR analysis of genes selected based on DNA array experiments revealed that estimation of the ratios of GATA6 to SPRR3 allows discrimination among normal esophageal epithelium, Barrett's dysplasia, and adenocarcinoma.
|
15833844 |
2005 |
|
Adenocarcinoma
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Positive correlations were observed between the expression of LGR5 and cytoplasmic GATA6 in adenoma (P=0.0005; r<sub>s</sub>=0.48) and adenocarcinoma samples (P=0.007; r<sub>s</sub>=0.38): However, no significant association was observed in normal mucosa (P=0.399).
|
29434936 |
2018 |
|
Adenocarcinoma
|
0.050 |
AlteredExpression
|
group |
BEFREE |
We studied GATA6, a TF gene that is frequently amplified or overexpressed in gastric, esophageal and pancreatic adenocarcinomas.
|
24317510 |
2014 |
|
Adenocarcinoma
|
0.050 |
Biomarker
|
group |
BEFREE |
Squamous cell carcinomas showed frequent genomic amplifications of CCND1 and SOX2 and/or TP63, whereas ERBB2, VEGFA and GATA4 and GATA6 were more commonly amplified in adenocarcinomas.
|
28052061 |
2017 |
|
Adenocarcinoma Of Esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
We conclude that selective gene amplification of GATA6 during EAC development sustains oncogenic lineage-survival of esophageal adenocarcinoma.
|
22375031 |
2012 |
|
Adenocarcinoma of large intestine
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In the present study, the expression of β-catenin, leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) and GATA6 was investigated during the transition from normal mucosa through to adenoma and adenocarcinoma in colorectal tissue sections obtained from 65 patients with a pathological diagnosis of colorectal adenocarcinoma and a history of adenoma.
|
29434936 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.020 |
Biomarker
|
disease |
BEFREE |
Thus, GATA6 and HOPX are critical nodes in a lineage-selective pathway that directly links effectors of airway epithelial specification to the inhibition of metastasis in the lung ADC subtype.
|
23707782 |
2013 |
|
Adenocarcinoma of lung (disorder)
|
0.020 |
Biomarker
|
disease |
BEFREE |
IHC analysis of GATA6 was performed with tissue microarray slides containing 348 LAs.
|
29469192 |
2018 |
|
Adenocarcinoma of pancreas
|
0.010 |
Biomarker
|
disease |
BEFREE |
Numerous genes were overexpressed, some of which have previously been implicated in pancreatic adenocarcinoma (GATA6, IGFBP3, IGFBP6), while others were detected for the first time (MEMO1, RIOK3).
|
20553613 |
2010 |
|
Adenoma
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Genetic deletion of Gata6 from mouse colon adenomas increases the levels of BMP factors, which signal to block self-renewal of tumour stem cells.
|
24952462 |
2014 |
|
Adenoma
|
0.040 |
Biomarker
|
group |
BEFREE |
GATA-6 mRNA was expressed in 19/19 adenomas and 9/10 carcinomas, and GATA-6 immunoreactivity was remarkably lower in adrenocortical carcinomas than in adenomas (p < 0.05).
|
15666845 |
2004 |
|
Adenoma
|
0.040 |
AlteredExpression
|
group |
BEFREE |
GATA-6 mRNA and protein expression was remarkably diminished in adrenocortical carcinomas as compared to normal adrenal cortex and adenomas (p<0.05).
|
15767045 |
2005 |
|
Adenoma
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Positive correlations were observed between the expression of LGR5 and cytoplasmic GATA6 in adenoma (P=0.0005; r<sub>s</sub>=0.48) and adenocarcinoma samples (P=0.007; r<sub>s</sub>=0.38): However, no significant association was observed in normal mucosa (P=0.399).
|
29434936 |
2018 |
|
Adrenal Cortical Adenoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We have now analyzed GATA-6 expression in 20 human adrenocortical adenomas and 16 carcinomas using Northern blot analysis and immunohistochemistry.
|
15767045 |
2005 |
|
Adrenocortical carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
GATA-6 mRNA was expressed in 19/19 adenomas and 9/10 carcinomas, and GATA-6 immunoreactivity was remarkably lower in adrenocortical carcinomas than in adenomas (p < 0.05).
|
15666845 |
2004 |
|
Adrenocortical carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
In contrast to GATA-6, we found upregulated cyclin-dependent kinase inhibitor p21 and proliferation marker Ki67 in adrenocortical carcinomas indicating that GATA-6 is not linked to cell proliferation in human adrenal tumors.
|
15767045 |
2005 |
|
Adult Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Cox regression analysis showed patient age, treatment, MGMT, GATA6 and CASP8 as independent predictors for glioblastoma patient outcome (p < 0.05).
|
22672670 |
2012 |
|
Agenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Induced pluripotent stem cells were created from a pancreas agenesis patient with a mutation in GATA6.
|
28196690 |
2017 |